Researchers in upstate New York are hopeful the work they’re doing may soon lead to new therapies for more cancer ...
According to MarketsandMarkets™, the CAR T-Cell Therapy Market is estimated to reach USD 13.78 billion by 2031 from USD 7.24 ...
Stylus Medicine, a member of BioSpace’s NextGen Class of 2026, launched in May 2025 to develop new, less complex genetic medicines. The company’s in vivo approach has attracted “intense” interest from ...
In a recent study published in Proceedings of the National Academy of Sciences, researchers engineered Chimeric Antigen Receptor (CAR) CD4 T cells, a technology originally revolutionized for cancer ...
Pharmaceutical Technology on MSN
Gilead acquires CAR-T specialist Arcellx for $7.8bn
Gilead is now waiting upon the FDA’s approval of anito-cel, Arcellx’s lead candidate, slated for December 2026.
T-cell therapy is based on engineered immune cells that find and destroy cancer cells. However, sometimes these cells also attack healthy tissues, causing side effects. An international team of ...
The Chosun Ilbo on MSN
In vivo CAR-T: Game-changing single injection for cancer
A method called **‘in vivo CAR-T (in vivo CAR-T·in vivo CAR-T)’** that directly alters immune cells within the body with a single injection is recently transforming the cancer treatment market. This ...
CAR T-cell therapies are individualized treatments approved for multiple hematologic malignancies, with improved management of adverse effects over time. Access to CAR T-cell therapies is limited by ...
Members of the CAR T Vision Steering Committee outline key issues around US and EU reimbursement and discuss potential solutions Am J Manag Care. 2025;31(Spec. No. 13 ...
Lymph nodes, considered the command centers of our immune system, often get swollen and stiff when fighting infection. Now, a UC Berkeley-led team of researchers has discovered that this mechanical ...
A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer treatment-could be a highly effective tool against atherosclerosis, the condition ...
Pharmaceutical Technology on MSN
Liberate Bio gains licences for myeloid-specific CAR design patents
The intellectual property will enhance Liberate Bio’s LNP platform for selective programming of monocytes and macrophages.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results